Serum concentration of taurochenodeoxycholic acid predicts clinically significant portal hypertension
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F23%3A00083840" target="_blank" >RIV/00023001:_____/23:00083840 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/23:10451893 RIV/00064165:_____/23:10451893
Result on the web
<a href="https://www.webofscience.com/wos/woscc/full-record/WOS:000890252700001" target="_blank" >https://www.webofscience.com/wos/woscc/full-record/WOS:000890252700001</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/liv.15481" target="_blank" >10.1111/liv.15481</a>
Alternative languages
Result language
angličtina
Original language name
Serum concentration of taurochenodeoxycholic acid predicts clinically significant portal hypertension
Original language description
Background & AimsSeverity of portal hypertension is usually quantified by measuring the hepatic venous pressure gradient (HVPG). However, due to its invasiveness, alternative markers are being sought. Bile acids (BA), being synthesized, metabolized, and transported by the liver, seem to have the potential to serve as endogenous markers. The aim of the present study was to determine whether serum BA reflect the severity of portal hypertension. MethodsWe correlated serum concentrations of individual BA with portal pressure (as HVPG) in an exploratory cohort of 21 cirrhotic patients with portal hypertension. The predictive potential of selected candidates was then confirmed in an independent validation cohort (n = 214). Additionally, nine previously published noninvasive markers were added to the stepwise logistic regression model to identify the most relevant ones, which were eventually used to create a prognostic index of portal hypertension. ResultsSerum levels of taurochenodeoxycholic acid (TCDCA) significantly correlated with HVPG and showed a high potential to predict clinically significant portal hypertension (HVPG >= 10 mm Hg: AUROC = 0.97 +/- 0.06). This was confirmed in the validation cohort (AUROC = 0.96 +/- 0.01). The predictive index (constructed based on AST/ALT, spleen diameter, and TCDCA concentration) was able to distinguish clinically significant portal hypertension with 95% sensitivity and 76% specificity. ConclusionsTCDCA seems to be a promising noninvasive marker of clinically significant portal hypertension. Its predictive potential may be further enhanced when it is combined with both the AST/ALT ratio and spleen diameter.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30201 - Cardiac and Cardiovascular systems
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Liver international
ISSN
1478-3223
e-ISSN
1478-3231
Volume of the periodical
43
Issue of the periodical within the volume
4
Country of publishing house
US - UNITED STATES
Number of pages
8
Pages from-to
888-895
UT code for WoS article
000890252700001
EID of the result in the Scopus database
2-s2.0-85142733634